The Diagnosis Value of Serum Marker in Stroke Associated With Nonvalvular Atrial Fibrillation.

Ischemic Stroke Clinical Trial

— CE  

Official title:

The Diagnosis Value of Serum Marker in Stroke Associated With Nonvalvular Atrial Fibrillation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02181374
• Other study ID #: Xijing-25
• Status: Recruiting
• Phase: N/A
• First received: June 3, 2014
• Last updated: December 30, 2015
• Start date: January 2012
• Est. completion date: September 2016

Study information

• Verified date: December 2015
• Source: Xijing Hospital
• Contact: Wen Jiang, MD
• Phone: 02984775361
• Email: jiangwen[@]fmmu.edu.cn
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to evaluate the diagnostic value of serum NT - proBNP in stroke associated with nonvalvular atrial fibrilltion.

Description:

All included in the cases in 7 days of blood samples, the detection of serum NT - proBNP.Through the single factor analysis to determine the serum NT - proBNP central source sex stroke prediction values.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• 18 = Age = 85;

• Meet the clinical diagnostic criteria for acute ischemic stroke;

• onset within 7 days;

Exclusion Criteria:

• Severe systemic disease (chronic inflammation, infection, blood system diseases, cancer, kidney failure, liver failure,heart failure);

• Nearly a month history of myocardial infarction;

• pregnant;

• Serious neurological disease that the diagnosis is unclear;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Atrial Fibrillation
• Ischemic Stroke
• Stroke

Locations

Country	Name	City	State
China	The Department of Neurology, Xijing Hospital	Xi'an	Shaanxi

Sponsors (4)

Lead Sponsor	Collaborator
Xijing Hospital	First Affiliated Hospital Xi'an Jiaotong University, Shaanxi Provincial People's Hospital, Tang-Du Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The diagnostic value of serum NT - proBNP in stroke associated with nonvalvular atrial fibrilltion	All included in the cases in 7 days of blood samples , the detection of serum NT - proBNP.Through the single factor analysis to determine the prediction values of serum NT - proBNP in stroke associated with nonvalvular atrial fibrilltion.	34 months	No